Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1639523 | 0.72 | — | — | |
| SCHEMBL838581 | 0.70 | — | — | |
| SCHEMBL11606239 | 0.69 | TNKS2 (0.40) | — | |
| SCHEMBL719722 | 0.69 | TSHR (0.52) | ACHE | |
| SCHEMBL29003926 | 0.68 | — | — | |
| SCHEMBL27658120 | 0.68 | — | — | |
| SCHEMBL1303260 | 0.65 | — | — | |
| SCHEMBL16954063 | 0.65 | — | — | |
| SCHEMBL1638474 | 0.65 | CYP3A4 (0.37) | — | |
| SCHEMBL8486856 | 0.65 | ACHE (0.36) | ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2982668-A2 | 2-(2-HYDROXYBIPHENYL-3-YL)-1H-BENZOIMIDAZOLE-5-CARBOXAMIDINE DERIVATIVES AS FACTOR VIIA INHIBITORS FOR THE TREATMENT OF THROMBOEMBOLIC DISORDERS | Pharmacyclics LLC (US) | 2016-02-10 | — | — | EP | disclosed |
| US-9181280-B2 | Factor VIIa inhibitor | PHARMACYCLICS LLC (US) | 2015-11-10 | — | — | US | disclosed |
| US-9162986-B2 | 2-(2-hydroxybiphenyl-3-yl)-1H-benzoimidazole-5-carboxamidine derivatives as factor VIIA inhibitors | PHARMACYCLICS LLC (US) | 2015-10-20 | — | — | US | disclosed |
| EP-1569912-B1 | 2-(2-HYDROXYBIPHENYL-3-YL)-1H-BENZOIMIDAZOLE-5-CARBOXAMIDINE DERIVATIVES AS FACTOR VIIA INHIBITORS | PHARMACYCLICS INC (US) | 2015-04-29 | — | — | EP | disclosed |
| US-20140378453-A1 | 2-(2-HYDROXYBIPHENYL-3-YL)-1H-BENZOIMIDAZOLE-5-CARBOXAMIDINE DERIVATIVES AS FACTOR VIIA INHIBITORS | PHARMACYCLICS LLC | 2014-12-25 | — | — | US | disclosed |
| US-20140221667-A1 | FACTOR VIIA INHIBITOR | PHARMACYCLICS, INC. (US) | 2014-08-07 | — | — | US | disclosed |
| US-8778625-B2 | 2-(2-hydroxybiphenyl-3-yl)-1H-Benzoimidazole-5-carboxamidine derivatives as factor VIIA inhibitors | PHARMACYCLICS, INC. (US) | 2014-07-15 | — | — | US | disclosed |
| US-8729117-B2 | Factor VIIa inhibitor | PHARMACYCLICS, INC. (US) | 2014-05-20 | — | — | US | disclosed |
| US-20140080879-A1 | FACTOR VIIA INHIBITOR | PHARMACYCLICS, INC. (US) | 2014-03-20 | — | — | US | disclosed |
| US-20130157298-A1 | 2-(2-Hydroxybiphenyl-3-yl)-1H-Benzoimidazole-5-Carboxamidine Derivatives as Factor VIIA Inhibitors | PHARMACYCLICS, INC. (US) | 2013-06-20 | — | — | US | disclosed |
| US-20110207939-A1 | FACTOR VIIA INHIBITOR | PHARMACYCLICS, INC. (US) | 2011-08-25 | — | — | US | disclosed |
| US-20090054432-A1 | 2-(2-Hydroxybiphenyl-3-yl)-1H-Benzoimidazole-5-Carboxamidine Derivatives as Factor VIIA Inhibitors | PHARMACYLICS, INC. A DELAWARE CORPORATION (US) | 2009-02-26 | — | — | US | disclosed |
| US-7479502-B2 | 2-(2-hydroxybiphenyl-3-yl)-1H-benzoimidazole-5-carboxamidine derivatives as factor VIIA inhibitors | PHARMACYCLICS, INC. (US) | 2009-01-20 | — | — | US | disclosed |
| US-20080275250-A1 | Factor Viia Inhibitor | PHARMACYCLICS, INC. (US) | 2008-11-06 | — | — | US | disclosed |
| US-20060205942-A1 | e.g. 2-{2-[545-carbamimidoyl-1H-benzoimidazol-2-yl)-6,2'-dihydroxy-5'-sulthmoyl-biphenyl-3-yl]-acetylsmino}-succinamic; anticoagulant, anticarcinogenic, antiinflammatory agent; deep vein thrombosis, rheumatoid arthritis, stroke | PHARMACYCLICS LLC | 2006-09-14 | — | — | US | disclosed |
| US-20050203094-A1 | 2-[5-(5-carbamimidoyl-1h-heteroaryl)]-6-hydroxybiphenyl-3-yl derivatives as factor viia inhibitors | AXYS PHARMACEUTICALS, INC. | 2005-09-15 | — | — | US | disclosed |
| US-20050176797-A1 | 2-[5-(5-Carbamimidoyl-1H-heteroaryl)-6-hydroxybiphenyl-3-YL]-succinic acid derivatives as factor viia inhibitors | AXYS PHARMACEUTICALS, INC. (US) | 2005-08-11 | — | — | US | disclosed |
| EP-1408963-A1 | 2- 5-(5-CARBAMIMIDOYL-1 i H /i -HETEROARYL)-6-HYDROXYBIPHENYL-3-YL]-SUCCINIC ACID DERIVATIVES AS FACTOR VIIA INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2004-04-21 | — | — | EP | disclosed |
| US-20030114457-A1 | 2- [5- (5-carbamimidoyl-1H-heteroaryl)-6-hydroxybiphenyl-3-yl]-succinic acid derivatives as factor viia inhibitors | AXYS PHARMACEUTICALS, INC. (US) | 2003-06-19 | — | — | US | disclosed |
| WO-2003006011-A1 | 2-[5-(5-CARBAMIMIDOYL-1H-HETEROARYL)-6-HYDROXYBIPHENYL-3-YL]-SUCCINIC ACID DERIVATIVES AS FACTOR VIIA INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2003-01-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110207939-A1 | FACTOR VIIA INHIBITOR | F7, F9, F5 | ACHE 1698/4885 |
| US-20060205942-A1 | e.g. 2-{2-[545-carbamimidoyl-1H-benzoimidazol-2-yl)-6,2'-dihydroxy-5'-sulthmoyl-biphenyl-3-yl]-acetylsmino}-succinamic; anticoagulant, anticarcinogenic, antiinflammatory agent; deep vein thrombosis, rheumatoid arthritis, stroke | F7, F9, F5 | ACHE 1140/4885 |
| US-20140080879-A1 | FACTOR VIIA INHIBITOR | F7, F9, F5 | ACHE 1698/4885 |
| US-20140221667-A1 | FACTOR VIIA INHIBITOR | F7, F9, F5 | ACHE 1698/4885 |
| US-20140378453-A1 | 2-(2-HYDROXYBIPHENYL-3-YL)-1H-BENZOIMIDAZOLE-5-CARBOXAMIDINE DERIVATIVES AS FACTOR VIIA INHIBITORS | F13B, HABP2, F7 | ACHE 2738/4885 |
| US-20050203094-A1 | 2-[5-(5-carbamimidoyl-1h-heteroaryl)]-6-hydroxybiphenyl-3-yl derivatives as factor viia inhibitors | F7, HABP2, F13B | ACHE 626/4885 |
| US-20090054432-A1 | 2-(2-Hydroxybiphenyl-3-yl)-1H-Benzoimidazole-5-Carboxamidine Derivatives as Factor VIIA Inhibitors | F13B, HABP2, F7 | ACHE 2738/4885 |
| US-20080275250-A1 | Factor Viia Inhibitor | F7, F9, F5 | ACHE 1626/4885 |
| US-20030114457-A1 | 2- [5- (5-carbamimidoyl-1H-heteroaryl)-6-hydroxybiphenyl-3-yl]-succinic acid derivatives as factor viia inhibitors | F7, F9, F5 | ACHE 3360/4885 |
| US-20050176797-A1 | 2-[5-(5-Carbamimidoyl-1H-heteroaryl)-6-hydroxybiphenyl-3-YL]-succinic acid derivatives as factor viia inhibitors | F7, F9, F5 | ACHE 3360/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.